{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-23-000087","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.580720+00:00","generated_at":"2026-06-15T08:37:57.028426+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Emergent Q1 revenue falls 46% to $165M, net loss $183M; updates FY guidance, divests travel health","bullets":["Total revenue $165.1M, down 46% YoY; net loss $183M ($3.65 loss per share) vs $3.7M loss in Q1 2022.","NARCAN sales up 8% to $100.4M; Anthrax MCM down 80% to $21.9M; CDMO revenue down 75%.","Adjusted EBITDA negative $101M vs positive $36M in Q1 2022; adjusted gross margin fell to 4%.","FY 2023 total revenue guidance unchanged at $1.1-1.2B; adjusted EBITDA raised to $100-150M; adjusted gross margin lowered to 39-42%.","Agreed to sell travel health business to Bavarian Nordic for up to $380M; expects to amend debt terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-23-000087","json":"https://secwatch.observer/filing/0001367644-23-000087.json","markdown":"https://secwatch.observer/filing/0001367644-23-000087.md","text":"https://secwatch.observer/filing/0001367644-23-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000087/0001367644-23-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000087/ebs-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:37:57.028426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a08aed1f1f2907dd181dfc2d48d1789eb7e577dd","claim":"Emergent BioSolutions Inc. reported the first quarter ended March 31, 2023 results: revenue $165M, net income $183M, EPS $(3.65) per diluted share.","evidence_excerpt":"Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000087/0001367644-23-000087-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$165M"},{"label":"Net income","value":"$183M"},{"label":"EPS","value":"$(3.65) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}